David A Lipson Selected Research

fluticasone furoate

1/2022	Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT Trial.
6/2021	Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial.
4/2021	InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations.
1/2021	Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT.
1/2021	InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions.
1/2021	Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD.
1/2021	Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial.
1/2021	Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
1/2021	Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis.
12/2020	24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David A Lipson Research Topics

Disease

67	Chronic Obstructive Pulmonary Disease (COPD) 08/2022 - 01/2004
8	Pneumonia (Pneumonitis) 12/2021 - 01/2018
3	Dyspnea (Shortness of Breath) 01/2021 - 01/2006
2	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2017 - 09/2015
2	Acute Lung Injury 01/2017 - 08/2012
2	Infections 09/2011 - 07/2005
2	Emphysema 05/2008 - 06/2002
2	Cystic Fibrosis (Mucoviscidosis) 03/2006 - 07/2005
1	Cardiovascular Diseases (Cardiovascular Disease) 06/2020
1	Disease Progression 10/2018
1	Wounds and Injuries (Trauma) 09/2015
1	Craniocerebral Trauma (Head Injury) 09/2015
1	Critical Illness (Critically Ill) 09/2015
1	Inflammation (Inflammations) 03/2012
1	Coinfection 09/2011
1	Heart Failure 09/2011
1	Human Influenza (Influenza) 09/2011
1	Myocardial Infarction 09/2011
1	Bacterial Infections (Bacterial Infection) 09/2011
1	Asthma (Bronchial Asthma) 09/2011
1	Sickle Cell Anemia (Hemoglobin S Disease) 09/2011
1	Pain (Aches) 05/2008
1	Renal Insufficiency (Renal Failure) 07/2005
1	Splenic Rupture 07/2003
1	Pulmonary Embolism 06/2002

Drug/Important Bio-Agent (IBA)

42	GSK573719IBA 08/2022 - 01/2016
40	vilanterolIBA 08/2022 - 01/2016
26	fluticasone furoate FDA Link 01/2022 - 01/2016
18	Adrenal Cortex Hormones (Corticosteroids)IBA 08/2022 - 01/2017
16	Bronchodilator Agents (Bronchodilators)IBA 08/2022 - 01/2004
8	Salmeterol Xinafoate (Serevent)FDA Link 08/2022 - 01/2004
7	Budesonide (Pulmicort)FDA LinkGeneric 01/2021 - 01/2017
7	Formoterol Fumarate (Oxis)FDA Link 12/2020 - 01/2004
6	Muscarinic AntagonistsIBA 01/2021 - 11/2017
6	GoldIBA 01/2019 - 01/2004
4	Tiotropium Bromide (Spiriva)FDA Link 01/2021 - 01/2004
3	Fluticasone (Cutivate)FDA LinkGeneric 01/2021 - 03/2012
2	BromidesIBA 08/2022 - 01/2020
2	Fibrinogen (Factor I)FDA Link 04/2021 - 03/2012
2	Biomarkers (Surrogate Marker)IBA 04/2021 - 03/2012
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 09/2011
2	Albuterol (Salbutamol)FDA LinkGeneric 01/2020 - 01/2020
2	tiotropium-olodaterolIBA 12/2018 - 11/2017
2	p38 Mitogen-Activated Protein KinasesIBA 09/2015 - 03/2012
2	Cholinergic Antagonists (Anticholinergics)IBA 01/2006 - 01/2004
1	omega-Chloroacetophenone (Mace)IBA 06/2020
1	PowdersIBA 01/2019
1	Therapeutic UsesIBA 10/2018
1	GlucocorticoidsIBA 05/2018
1	Complement System Proteins (Complement)IBA 01/2018
1	alunacedase alfaIBA 01/2017
1	Angiotensin-Converting Enzyme 2IBA 01/2017
1	dilmapimodIBA 09/2015
1	Adenosine (Adenocard)FDA LinkGeneric 08/2012
1	6- (5- ((cyclopropylamino)carbonyl)- 3- fluoro- 2- methylphenyl)- N- (2,2- dimethylprpyl)- 3- pyridinecarboxamideIBA 03/2012
1	Tobramycin (Nebcin)FDA LinkGeneric 07/2005
1	Helium-3IBA 06/2002

Therapy/Procedure

44	Therapeutics 08/2022 - 01/2004
28	Nebulizers and Vaporizers (Inhaler) 03/2022 - 01/2017
2	Lung Transplantation 03/2006 - 06/2002
1	Dry Powder Inhalers 01/2019
1	Chest Tubes (Chest Tube) 05/2008
1	Postoperative Care 05/2008
1	Pneumonectomy (Lung Volume Reduction) 05/2008
1	Nutrition Therapy (Medical Nutrition Therapy) 01/2006
1	Splenectomy 07/2003
1	Laparotomy 07/2003